{"id":293640,"date":"2025-09-26T00:00:00","date_gmt":"2025-09-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2024-biopharma-psoriasis-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:24:55","modified_gmt":"2026-03-31T10:24:55","slug":"dlsfim0005-2026-biopharma-psoriasis-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2026-biopharma-psoriasis-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Psoriasis &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly\u2019s Taltz, Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya, AbbVie\u2019s Skyrizi) are fiercely competing with the established agents Humira and Stelara, effectively earning a strong position in a crowded market due to their greater efficacy, more-convenient dosing, and faster onset of action. The availability of <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s oral <abbr title=\"tyrosine kinase 2\">TYK2<\/abbr> inhibitor Sotyktu and UCB\u2019s <abbr title=\"interleukin\">IL<\/abbr>-17 A\/F dual inhibitor Bimzelx has expanded dermatologists\u2019 treatment armamentarium and increased competition among targeted therapies. Moreover, several oral\u2014and thus more-convenient\u2014agents for psoriasis, including piclidenoson, which has a novel mechanism of action, are expected to launch, further fueling competition in this space. Nevertheless, substantial unmet need in the treatment of psoriasis remains (e.g., agents that induce long-term remission for patients with severe disease, more-affordable therapies for patients with mild disease).<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXP238214188 BCX0 round-bullets\">\n<li>How do interviewed <abbr title=\"key opinion leader\">KOL<\/abbr>s view the efficacy and safety of the <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors (Cosentyx, Taltz, Siliq \/ Lumicef, Bimzelx) and the <abbr title=\"interleukin\">IL<\/abbr>-23 inhibitors (Tremfya, Ilumya, Skyrizi), and where are \/ will these agents be positioned in the psoriasis treatment algorithm?<\/li>\n<li>How is the oral <abbr title=\"tyrosine kinase 2\">TYK2<\/abbr> inhibitor Sotyktu affecting apremilast\u2019s (Amgen\u2019s Otezla) patient share, and how do the two agents compare on efficacy and safety attributes?<\/li>\n<li>How does the availability of adalimumab biosimilars in the United States impact the psoriasis market?<\/li>\n<li>What unmet needs remain in the treatment of psoriasis? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW255089486 BCX8 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li><span class=\"TextRun SCXW153743969 BCX8\" data-contrast=\"none\" lang=\"EN-US\" avenir next lt pro pro_embeddedfont pro_msfontservice sans-serif xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW153743969 BCX8\" data-ccp-parastyle=\"Body Text\" style=\"-webkit-user-drag: none; -webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; user-select: text;\">Gauge <\/span><span class=\"NormalTextRun SCXW153743969 BCX8\" data-ccp-parastyle=\"Body Text\" style=\"-webkit-user-drag: none; -webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; user-select: text;\">the <\/span><span class=\"NormalTextRun SCXW153743969 BCX8\" data-ccp-parastyle=\"Body Text\" style=\"-webkit-user-drag: none; -webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; user-select: text;\">commercial outlook and <\/span><span class=\"NormalTextRun SCXW153743969 BCX8\" data-ccp-parastyle=\"Body Text\" style=\"-webkit-user-drag: none; -webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; user-select: text;\">impact<\/span><span class=\"NormalTextRun SCXW153743969 BCX8\" data-ccp-parastyle=\"Body Text\" style=\"-webkit-user-drag: none; -webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; user-select: text;\"> of key market events.<\/span><\/span> <\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-293640","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293640\/revisions"}],"predecessor-version":[{"id":575730,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293640\/revisions\/575730"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=293640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}